Hypera SA AI Stock Analysis
Want to see HYPMY full AI Analyst Report?
Hypera SA (HYPMY) AI Stock Analysis
Hypera SA
(Other OTC:HYPMY)
The score is driven primarily by solid underlying financial performance (strong margins, earnings rebound, and improving leverage) and supportive valuation (low P/E and high dividend yield). These positives are tempered by weak technicals (price below key moving averages with bearish momentum) and, to a lesser extent, near-term execution/margin uncertainty discussed on the earnings call (flu weakness and launch-related expense/margin dilution).
Hypera SA (HYPMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.80B
- Dividend Yield
- 6.58%
- Average Volume (3M)
- 8,521
- Price to Earnings (P/E)
- 8.3
- Beta (1Y)
- 0.69
- Revenue Growth
- 40.78%
- EPS Growth
- 122.10%
- Country
- US
- Employees
- 10,564
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Hypera SA Business Overview & Revenue Model
Company Description
Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Adde...
How the Company Makes Money
Hypera makes money primarily by selling healthcare products in Brazil, generating revenue from the commercial sale of its portfolio to pharmacies, drugstore chains, distributors, and other retail channels. Its key revenue streams come from (1) brande...
Hypera SA Earnings Call Summary
The call was broadly positive. Hypera delivered solid revenue, EBITDA, net income, cash conversion, working-capital, and leverage improvements, while Semavy's launch materially exceeded initial expectations and expanded the company's chronic-care portfolio. The main challenges were weaker flu-related demand, higher launch and marketing expenses, short-term Semavy margin dilution, a slower institutional-market ramp, and uncertainty around near-term category and margin trends. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects October sell-out growth of low teens, with the base portfolio at mid-single digits and the remainder coming from Semavy; Semavy is expected to double the approximately 94,000 units sold in the previous month and continue leading until the end of 2027. The flu category will probably see a negative impact until the first quarter, with recovery expected in the third quarter of 2027, while El Niño should continue until the end of the first quarter or the beginning of the second quarter of 2027. Management has not changed its expectations for margins and does not expect any variations that will change the trends in the second and third quarters; investments will reduce starting in 2027, and the company expects cash generation for next year to be slightly higher than this year. The goal is to reach 1.5x net debt to EBITDA, with management believing it will be close to that level at the end of 2027, while institutional-market sales are targeted at BRL 1.5 billion by 2028, or maybe for the future, maybe for 2030.
Hypera SA Financial Statement Overview
Summary
Fundamentals are solid overall: strong profitability (TTM gross margin ~59%, net margin ~20%), revenue and net income rebounded versus 2025, and leverage improved with lower debt and higher equity. The main offset is softer recent cash-flow momentum (TTM FCF growth ~-9.9% and weaker operating cash flow coverage of debt), plus margins below the 2022–2023 peak.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.03B | 7.70B | 7.44B | 7.91B | 7.55B | 5.94B |
| Gross Profit | 5.48B | 4.55B | 4.38B | 5.00B | 4.76B | 3.80B |
| EBITDA | 2.93B | 2.26B | 2.23B | 2.88B | 2.77B | 2.16B |
| Net Income | 1.81B | 1.20B | 1.34B | 1.65B | 1.70B | 1.33B |
Balance Sheet | ||||||
| Total Assets | 30.17B | 25.16B | 24.56B | 24.51B | 23.76B | 19.82B |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 1.65B | 1.74B | 2.58B | 2.86B | 2.29B |
| Total Debt | 7.90B | 9.34B | 9.40B | 9.96B | 9.68B | 7.41B |
| Total Liabilities | 15.27B | 12.63B | 12.46B | 12.99B | 13.10B | 9.98B |
| Stockholders Equity | 14.91B | 12.52B | 12.10B | 11.50B | 10.65B | 9.83B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.78B | 1.77B | 1.58B | 529.34M | 560.25M |
| Operating Cash Flow | 2.25B | 2.57B | 2.54B | 2.40B | 2.04B | 1.40B |
| Investing Cash Flow | -588.51M | -689.50M | -592.44M | -791.19M | -1.74B | -4.41B |
| Financing Cash Flow | -1.48B | -1.98B | -2.79B | -1.89B | 278.95M | 557.06M |
Hypera SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPMY, the sentiment is Negative. The current price of 4.03 is below the 20-day moving average (MA) of 4.41, below the 50-day MA of 4.63, and below the 200-day MA of 4.35, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 39.84 is Neutral, neither overbought nor oversold. The STOCH value of 79.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPMY.
Hypera SA Peers Comparison
Overall Rating
- HYPMY68Neutral
RDY67Neutral
HLN62Neutral
AMRX58Neutral
VTRS58Neutral
PRGO52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HYPMY | 68Neutral | $2.79B | 8.32 | 12.98% | 6.58% | 40.78% | 122.10% |
| RDY | 67Neutral | $12.32B | 40.98 | 7.37% | 0.56% | -10.52% | -55.45% |
| HLN | 62Neutral | $39.05B | 18.70 | 9.89% | 1.36% | 4.99% | 12.37% |
| AMRX | 58Neutral | $7.45B | 50.49 | 131.71% | ― | 8.88% | 2272.07% |
| VTRS | 58Neutral | $23.90B | -39.73 | -4.24% | 2.28% | 4.80% | 82.97% |
| PRGO | 52Neutral | $2.34B | -1.30 | -68.13% | 7.01% | -4.45% | -3289.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HYPMY | Hypera S.A. Sponsored ADR | 4.03 | -0.67 | -14.18% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.84 | 1.05 | 7.58% | |
| VTRS | Viatris, Inc. | 21.06 | 10.52 | 99.89% | |
| PRGO | Perrigo Company | 16.55 | 3.78 | 29.64% | |
| AMRX | Amneal Pharma | 21.71 | 10.19 | 88.45% | |
| HLN | Haleon PLC Sponsored ADR | 9.10 | -0.61 | -6.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026